Anesthesiology · 2011 · 244 citations · 26 references
MedicineHematologyPharmacologyCardiovascular PharmacotherapyClinical PharmacologyHemostasisAnticoagulant TherapyAnticoagulation TherapyAntithrombotic TherapyHemostatic AgentsThrombosisThrombosis PreventionActivated Clotting TimeAnticoagulant PharmacologyAntithrombotic-associated BleedingMinimal Effective DoseProthrombin Complex Concentrate UseRabbit ModelsRecombinant Activated Factor ViiThrombin Generation Assays
BACKGROUND: As a potent anticoagulant agent, rivaroxaban exposes a risk of bleeding. An effective way to reverse its effects is needed. Objectives were to study efficacy and safety of recombinant activated factor VII (rFVIIa) and prothrombin complex concentrate (PCC) to reverse the anticoagulant effect of an overdose of rivaroxaban in a rabbit model of bleeding and thrombosis. METHODS: First, a dose-ranging study assessed the minimal rivaroxaban dose that increased bleeding. Then, 48 anesthetized and ventilated rabbits were randomized into four groups: control (saline), rivaroxaban (rivaroxaban and saline), rFVIIa (rivaroxaban and rFVIIa), and PCC (rivaroxaban and PCC). The Folts model was applied: a stenosis and an injury were carried out on the carotid artery, inducing thrombosis, detected as cyclic flow reductions, which were recorded over 20 min. Then the following were measured: ear immersion bleeding time, clotting times, anti-Xa activity, thrombelastometric parameters, and thrombin generation test. Ultimately, a hepatosplenic section was performed and the total amount of blood loss after 15 min was evaluated as primary endpoint. RESULTS: Rivaroxaban increased blood loss (17 g [8-32] vs. 7 g [5-18] for control (median [range]), P = 0.0004), ear bleeding time, clotting times, thrombelastographic clotting time, and decreased thrombin generation. In contrast, rFVIIa decreased ear bleeding time (92 s [65-115] vs. 140 s [75-190], P < 0.02), but without efficacy on blood loss. PCC and rFVIIa decreased activated partial thromboplastin time as well as thrombelastographic clotting time. Regarding safety, neither rFVIIa nor PCC increased cyclic flow reductions. CONCLUSION: rFVIIa and PCC partially improved laboratory parameters, but did not reverse rivaroxaban induced-bleeding.
26
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
New England Journal of Medicine · 2010 · 3.2K citations · Full text
Pharmacology and Management of the Vitamin K Antagonists
Jack Ansell, Jack Hirsh, Elaine M. Hylek et al. · CHEST Journal · 2008 · 2.1K citations
Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate
Elise S. Eerenberg, Pieter W. Kamphuisen, Meertien K. Sijpkens et al. · Circulation · 2011 · 1.4K citations · Full text